Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: October 23, 2018
Pages: 105
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: S964BB40003EN
Leaflet:

Download PDF Leaflet

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1. The company’s gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark’s SPK-RPE65 is intentended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It collaborates with pharma and biotech companies for its research and development activities. Spark is headquartered in Philadelphia, Pennsylvania, the US.

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion/divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Spark Therapeutics Raises USD73 Million in Series B Financing
Spark Therapeutics Raises US$50 Million In Venture Financing
Partnerships
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School
Licensing Agreements
Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics
Spark Therapeutics Enters into Licensing Agreement with Genethon
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences
Pfizer Amends Licensing Agreement with Spark Therapeutics
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies
Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies
Equity Offering
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares
Spark Therapeutics Raises USD181 Million in Public Offering of Shares
Spark Therapeutics Raises USD107 Million in Public Offering of Shares
Genable Tech to Raise USD15.7 Million in Financing
Spark Therapeutics Raises USD185 Million in IPO
Asset Transactions
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million
Acquisition
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million
Spark Therapeutics Inc - Key Competitors
Spark Therapeutics Inc - Key Employees
Spark Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Strategy And Business Planning
Oct 11, 2018: Governor Wolf Announces Spark Therapeutics to Expand in West Philadelphia with New Facility, 500 New Jobs
Financial Announcements
Aug 07, 2018: Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
May 08, 2018: Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
Feb 20, 2018: Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress
Nov 07, 2017: Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
Aug 02, 2017: Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress
May 09, 2017: Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress
Feb 22, 2017: Spark Therapeutics Reports 2016 Financial Results and Business Highlights
Corporate Communications
Jan 04, 2018: Spark Therapeutics Announces Addition of Robert J. Perez to Board of Directors
Sep 25, 2017: Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer
Product News
12/19/2017: FDA Approves Spark Therapeutics LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
11/02/2017: Spark Therapeutics to Participate in Multiple Upcoming Conferences
10/12/2017: FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
07/10/2017: Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
06/23/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
04/06/2017: Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium
04/04/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium
03/26/2018: Boy with Inherited Blindness First to Receive FDA-Approved Gene Therapy at Bascom Palmer
03/21/2018: Childrens Hospital Los Angeles Treats First Patient on the West Coast Using Gene Therapy
03/20/2018: Mass. Eye and Ear performs first FDA-approved gene therapy procedure for inherited disease
03/05/2018: Horizon Blue Cross Blue Shield Provides Update on Voretigene neparvovec-rzyl (Luxturna)
01/03/2018: Spark Therapeutics Announces First-of-their-kind Programs to Improve Patient Access to LUXTURNA (voretigene neparvovec-rzyl), a One-time Gene Therapy Treatment
01/03/2018: Spark's Gene Therapy Treatment for Blindness LUXTURNA to Cost $850,000
Product Approvals
Oct 19, 2017: Spark Therapeutics: Gene therapy continues to advance
Jul 31, 2017: Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA (voretigene neparvovec)
Jul 20, 2017: Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA (voretigene neparvovec) from FDA
Jul 17, 2017: Spark Therapeutics' Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA
May 18, 2017: Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene
Mar 01, 2017: Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
Clinical Trials
Oct 08, 2018: Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
Feb 23, 2018: Spark Therapeutics to Participate in Multiple Conferences in March
Nov 10, 2017: Three-year Follow-up Phase 3 Data Provide Additional Information on Efficacy, Durability and Safety of Investigational LUXTURNA (voretigene neparvovec) in Patients with Biallelic RPE65-mediated Inherited Retinal Disease
Oct 12, 2017: Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy
Sep 06, 2017: Spark Therapeutics Announces Publication of Study Confirming Novel Tests Validity, Reliability and Ability to Detect Change in Functional Vision
Jul 13, 2017: Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec
Jan 09, 2017: Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Spark Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Spark Therapeutics Raises USD73 Million in Series B Financing
Spark Therapeutics Raises US$50 Million In Venture Financing
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School
Novartis Enters into Licensing and Supply Agreement with Spark Therapeutics
Spark Therapeutics Enters into Licensing Agreement with Genethon
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences
Pfizer Amends Licensing Agreement with Spark Therapeutics
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies
Spark Therapeutics Amends Licensing Agreement with University of Iowa Research Foundation
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia
Spark Therapeutics Amends Licensing Agreement with University of Pennsylvania
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares
Spark Therapeutics Raises USD181 Million in Public Offering of Shares
Spark Therapeutics Raises USD107 Million in Public Offering of Shares
Genable Tech to Raise USD15.7 Million in Financing
Spark Therapeutics Raises USD185 Million in IPO
JAZZ Pharma to Acquire Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million
Spark Therapeutics Inc, Key Competitors
Spark Therapeutics Inc, Key Employees
Spark Therapeutics Inc, Subsidiaries

LIST OF FIGURES

Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Spark Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018
Skip to top


Ask Your Question

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: